Galapagos to acquire all outstanding shares of CellPoint & AboundBio in an all-cash transaction which consists of $131.20M up front for CellPoint with additional fees of $104.96M upon achievement of milestones & $14M for AboundBio
The acquisition will combine CellPoint’s decentralized point-of-care manufacturing model with Lonza & AboundBio’s human Ab-based capabilities & biological drug capabilities to develop 3 additional CAR-T candidates for the clinic over the next 3yrs.
The acquisition also broadens Galapagos’ portfolio & capabilities. The results from an ongoing 2 P-I/IIa studies for r/rNHL & r/rCLL, which are clinically validating the decentralized production platform with CD19 CAR-T are anticipated in H1’23
Ref: GlobalNewswire | Image: Galapagos
